This article covers a Series A round on 20 October 2025 for CoMind, a London-based health tech company that has developed an optical neuro-monitoring platform to non-invasively measure cerebral blood flow, autoregulation and intracranial pressure, founded by James Dacombe. The company raised £74.48m in a round led by Plural with participation from LocalGlobe.
CoMind offers an optical platform that uses non-invasive sensors to monitor brain activity at the bedside. Its primary use is continuous bedside measurement of brain health indicators to support clinical monitoring and decision-making.
Hospitals face risky, expensive, and invasive options to monitor brain activity and pressure in critically ill patients.
CoMind explains that it uses an optical, non-invasive neuro-monitoring platform to measure cerebral blood flow, autoregulation and intracranial pressure. This reduces reliance on risky invasive tests and supports earlier, better informed care decisions in intensive care.
CoMind raised more than £74.5m ($100m) in a Series A round led by Plural, alongside investor Angelini Ventures and other existing backers. This makes it the 3rd largest funding round in October 2025 (53 recorded). By size, the round comes in 29th for 2025 (525 recorded) in the Startupmag database, as of 20 October 2025.
For details on how Startupmag compiles its rankings, view our Methodology.
The key investors were:
In the funding announcement, Taavet Hinrikus from Plural said:
This is only the beginning. CoMind plans to expand its product portfolio to measure additional physiological parameters and develop CoVision, an AI platform that transforms sensor data into predictive insights, identifying complications early and personalising treatment.
If you're researching potential backers in this space:
James Dacombe is the founder of CoMind.
CoMind is based in London, UK.
CoMind operates in the health technology sector. The sector makes devices and software to prevent, diagnose and treat illness. In simple terms, it uses technology to help doctors and patients.
Key trends and challenges in Healthtech:
Optical and wearable sensors can measure cerebral blood flow and pressure without surgery, reducing patient risk.
Devices often require FDA or MHRA clearance and large clinical trials before intensive care adoption.
AI models aim to predict complications early, but require transparent algorithms and good quality data to be trusted.
For a deeper look at innovation in this space, see the healthtech startups in the UK.
Investor | Sector | Stage | Activity | Team | Connect |
---|---|---|---|---|---|
![]() Plural | 8 investment(s) investment(s) | 5 contacts contacts | |||
![]() LocalGlobe | 20 investment(s) investment(s) | 12 contacts contacts | |||
![]() Octopus Ventures | 39 investment(s) investment(s) | 14 contacts contacts | |||
![]() Crane Venture Partners | 2 investment(s) investment(s) | 7 contacts contacts | |||
![]() BackedVC | 26 investment(s) investment(s) | 3 contacts contacts | |||
![]() Entrepreneur First | 11 investment(s) investment(s) | 10 contacts contacts |
Click here for a full list of 7,233+ startup investors in the UK